Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights

Executive Summary

Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.

You may also be interested in...



Pharma Pushes For Stronger ‘March In’ Rule Despite Changing Political Dynamics, COVID Complications

With COVID-19 drawing new attention to the government’s investment in R&D and high drug prices, lower drug pricing advocates are optimistic the Biden team will a Trump-era attempt to carve out a medication’s price from patent breaking criteria. The drug industry isn’t just defending Trump’s plan – its trying to strengthen it.

US-Funded Research On Remdesivir Did Not Produce ‘Patentable’ Discoveries

US government agencies were given the right to pursue patents on remdesivir in research contracts negotiated with Gilead but did not do so, the Government Accountability Office reports. 

Becerra Takes The Helm At HHS; More Visibility On Administration’s Drug Pricing Priorities To Follow

Becerra’s HHS has a new crop of former Capitol Hill staffers in its policy ranks who are well versed on legislation in the health care realm, including prescription drug pricing reform. That will help advance the Administration’s agenda.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel